



DOCTORAL THESIS

Phytochemical and pharmacological studies of the root of ilex pubescens

Wang, Jingrong

Date of Award: 2008

Link to publication

General rightsCopyright and intellectual property rights for the publications made accessible in HKBU Scholars are retained by the authors and/or other copyright owners. In addition to the restrictions prescribed by the Copyright Ordinance of Hong Kong, all users and readers must also observe the following terms of use:

- Users may download and print one copy of any publication from HKBU Scholars for the purpose of private study or research
 Users cannot further distribute the material or use it for any profit-making activity or commercial gain
 To share publications in HKBU Scholars with others, users are welcome to freely distribute the permanent URL assigned to the publication

Download date: 29 Nov, 2021

Phytochemical and Pharmacological Studies of the Root of *Ilex pubescens*

WANG Jingrong

A thesis submitted in partial fulfillment of the requirements

for the degree of

Doctor of Philosophy

Principal Supervisor: Prof. LIU Liang

Hong Kong Baptist University

March 2008

ABSTRACT

Maodongqing (毛冬青, MDQ), the root of *Ilex pubescens* Hook. et Arn. (Aquifoliaceae), is widely used in southern China for treatment of cardiovascular, peripheral vascular and inflammatory diseases. Owing to its efficacy and safety, this herb has been developed into many single herbal preparations and proprietary products. However, the anti-inflammatory and anti-thrombotic activities and their relevant active principles of MDQ have not been well investigated. In the current work, an activity-guided phytochemical study and pharmacological studies were undertaken in order to clarify the underlying scientific foundations of the therapeutic effects of MDQ, and further provide evidence for exploiting and utilizing MDQ. The results were shown as below:

Anti-thrombotic effects of nine fractions isolated from the n-BuOH layer of ethanol extract of MDQ by column chromatography were examined by using Kappa-carrageenan-induced tail thrombosis as a testing model. A phenolic fraction, Fr. 5, was identified as the bioactive fraction possessing anti-thrombotic activity. Chemical investigation on Fr. 5 led to the isolation of two novel hemiterpene glucosides whose structures were elucidated on the basis of spectroscopic and chemical evidences as 2-(trans-caffeoyloxy)methyl-3-hydroxy-1-butene-4-O- β -D-glucopyranoside(pubescenoside A) and 2-hydroxymethyl-3-trans-caffeoyloxy-1-butane-4-O- β -D-glucopyranoside (pubescenoside B). These two hemiterpene glucosides were found to have anti-platelet aggregation activity by using high shear stress-induced platelet aggregation test.

Anti-inflammatory activities of the nine fractions of MDQ were assayed with carrageenan-induced paw edema in rats. A saponin fraction, Fr.8-2, was identified as the bioactive fraction with the most potent anti-inflammatory effect among those nine fractions. Two novel triterpene saponins named as pubescenosides C and D together with five known triterpene saponins were isolated from Fr.8-2. Based on spectroscopic and chemical evidences, the structures of pubescenosides C and D were elucidated as $3-O-\beta$ -D-glucopyranosyl($1\rightarrow 2$)- β -D-xylopyranosyl-urs-12,18-dien-(20β -methyl)-28-oic acid $28-O-\beta$ -D-glucopyranosyl ester and $3-O-\alpha$ -L-rhamnopyranosyl ($1\rightarrow 2$)- β -D-glucopyranosyl ester, respectively. The five known triterpene saponins were elucidated as ilexsaponin B₁, B₂, B₃, A₁ and chikusetsusaponin IVa. HPLC fingerprinting of Fr.8-2 demonstrated that more than 70 % of the components in this fraction could be chemically identified.

Subsequently, in vivo anti-inflammatory and analgesic effects of Fr. 8-2 were

comprehensively evaluated. As a result, it showed a significant suppression on the paw edema of rats induced by subplantar injection of carrageenan or histamine when given intraperitoneally at dosages ranging from 12.5 to 100 mg/kg of Fr.~8-2 in rats, demonstrating its potent anti-inflammatory activity on acute inflammation model. This fraction was also proven to exert analgesic effect, because it could significantly inhibit acetic acid-induced abdominal writhing response of mice and prolong the time required for mice tail flick after exposure to a source of radiant heat at the oral dosages of 100 and 200 mg/kg. Mechanistic studies showed that the anti-inflammatory effect of Fr.~8-2 was closely related to the selective inhibition on cyclooxygenase-2 (COX-2) expression, and overall attenuation of the ratio of pro-inflammatory /anti-inflammatory cytokines which was resulted from significant inhibition on the pro-inflammatory cytokines (IL-1, IL-6 and TNF- α) and elevation of the anti-inflammatory cytokines (IL-1) production at the sites of inflammation.

In conclusion, this research revealed that MDQ has multiple functions, such as anti-thrombotic, anti-inflammatory and analgesic actions, which may attribute to the unusual hemiterpene glucosides and triterpene saponins in this herb. These results supported the clinical usage of MDQ in treating cardiovascular, peripheral vascular diseases and various inflammatory conditions. Meanwhile, *Fr.* 8-2, a triterpene saponin fraction whose chemical components were largely identified, and pharmacological activities were well verified, is expected to be developed as a botanical drug for anti-inflammation

TABLE OF CONTENTS

| DECLARATION | i |
|--|------|
| ABSTRACT | ii |
| ACKNOWLEDGEMENTS | iv |
| TABLE OF CONTENTS | vi |
| LIST OF FIGURES | xii |
| LIST OF TABLES | XV |
| LIST OF SCHEMES | xvi |
| LIST OF ABBREVIATIONS | xvii |
| CHAPTER 1 INTRODUCTION AND DESIGN OF THE RESEARCH | 1 |
| 1.1 General Introduction on <i>Ilex pubescens</i> Hook. et Arn | 2 |
| 1.2 Clinical Applications of MDQ and Ilexonin A | 12 |
| 1.2.1 Treatment for Heart Diseases | 12 |
| 1.2.2 Treatment for Peripheral Vascular Diseases | 15 |
| 1.2.3 Treatment for Cerebrovascular Diseases | 18 |
| 1.2.4 Treatment for Respiratory Infectious Diseases | 19 |
| 1.2.5 Treatment for Acute and Chronic Inflammatory Diseases | 20 |
| 1.2.6 Other Applications | 22 |
| 1.2.7 Adverse Effects | 22 |
| 1.3 Pharmacological Activities of MDQ and Ilexonin A | 23 |
| 1.3.1 Actions on the Cardiovascular System | 23 |
| 1.3.2 Anti-thrombotic Effect | 31 |
| 1.3.3 Anti-inflammatory Effect | 34 |

| 1.3.4 Other Activities | 36 |
|--|-----------|
| 1.3.5 Toxicity | 36 |
| 1.3.6 Summary | 37 |
| 1.4 Chemical Investigations on <i>Ilex pubescens</i> | 40 |
| 1.4.1 Triterpenes | 40 |
| 1.4.2 Triterpene Saponins | 41 |
| 1.4.3 Coumarins | 43 |
| 1.4.4 Lignans | 43 |
| 1.4.5 Phenylpropanoid | 44 |
| 1.4.6 Phenolics and Other Compounds | 45 |
| 1.5 Introduction to Triterpene and Triterpene Saponins | 47 |
| 1.5.1 Definition | 48 |
| 1.5.2 Structural Types | 49 |
| 1.5.3 Occurrence | 49 |
| 1.5.4 Biological Activities | 51 |
| 1.6 Structural Elucidation of Organic Compounds with Spectroscopic Technique | s53 |
| 1.6.1 Mass Spectrometry | 54 |
| 1.6.2 NMR Spectroscopy | 59 |
| 1.6.3 X-ray Crystallography | 64 |
| 1.7 Aims, Objectives and Design of the Study | 64 |
| 1.7.1 Aims and Objectives | 64 |
| 1.7.2 Design of the Study | 66 |
| 1.8 Structure of the Thesis | 71 |
| CHAPTER 2 SCREENING FOR THE BIOACTIVE FRACTIONS WITH | |
| ANTI-THROMBOTIC ACTIVITY AND IDENTIFICATION OF THE | |
| RELEVANT CONSTITUENTS | 73 |
| 2.1 Introduction | 74 |
| 2.2 Experimental | , . Ω1 |

| | 2.2.1 | Materials and Methods. | 81 |
|-------------|-------|--|------|
| | 2.2.2 | Preparation of Fractions of MDQ | 83 |
| | 2.2.3 | Carrageenan-induced Tail Thrombosis in Mice | 86 |
| | 2.2.4 | Isolation of Pubescenosides A (1) and B (2) | 86 |
| | 2.2.5 | Shear-induced Platelets Aggregation | 89 |
| | 2.2.6 | Statistical Analysis | 90 |
| 2.3 | Resu | lts | 90 |
| | 2.3.1 | Effects of MDQ Fractions on Carrageenan-induced Tail Thrombosis in | Mice |
| | | | 90 |
| | 2.3.2 | Structure Elucidation of Pubescenosides A (1) and B (2) | 93 |
| | 2.3.3 | Activities of Pubescenosides A and B on Platelet Aggregation Induced by | ру |
| | | High Shear Stress | 101 |
| 2.4 | Disc | ussions | 103 |
| | 2.4.1 | Identification of the Bioactive Fractions | 103 |
| | 2.4.2 | Chemical Constituents of the Bioactive Fraction | 104 |
| | 2.4.3 | In vitro Activities of Pubescenosides A and B on Platelets Aggregation | 108 |
| 2.5 | Conc | elusions | 110 |
| СН | APTE | R 3 SCREENING FOR THE BIOACTIVE FRACTIONS WITH | |
| | | FLAMMATORY ACTIVITY AND IDENTIFICATION OF THE | |
| | | NT CONSTITUENTS | 111 |
| 3 1 | Intro | duction | 112 |
| 5.1 | | In Vivo Models for Anti-inflammatory Studies | |
| | | In Vitro Models of Inflammation | |
| | | Models in the Current Study | |
| 3 2 | | rimental | |
| <i>ع</i> .د | | Materials and Methods | |
| | | | |
| | | Induction of Acute Inflammation in Rat Hind Paws by Carrageenan Isolation of Triternene Sanonins from Er. 8-2 | 124 |
| | | | |

| | 3.2.4 | Chemical Profiling Analysis of Fr. 8-2 Using HPLC Technique | 131 |
|-------------|-------|---|-----|
| | 3.2.5 | Statistical Analysis | 132 |
| 3.3 | Resu | lts and Discussions | 132 |
| | 3.3.1 | Effects of MDQ Fractions on Carrageenan-induced Paw Edema in Rats | 132 |
| | 3.3.2 | Structure Elucidation of Two New Triterpene Saponins Pubescenosides C | (3) |
| | | and D (4) | 134 |
| | 3.3.3 | Structure Elucidation of the Known Triterpene Saponins | 144 |
| | 3.3.4 | Chemical Profiles of Fr. 8-2 Characterized by HPLC Fingerprinting | 154 |
| 3.4 | Disc | ussions and Conclusions | 155 |
| СНА | APTE | R 4 <i>IN VIVO</i> ANTI-INFLAMMATORY AND ANALGESIC | |
| AC T | ΓΙVΙΤ | TES OF FR. 8-2 | 158 |
| 4.1 | Intro | ductionduction | 159 |
| 4.2 | Expe | rimental | 162 |
| | 4.2.1 | Drugs and Reagents | 162 |
| | 4.2.2 | Animals | 162 |
| | 4.2.3 | Induction of Acute Inflammation in Rat Hind Paws by Injection of | |
| | | Carrageenan | 163 |
| | 4.2.4 | Induction of Acute Inflammation in Rat Hind Paws by Injection of Histami | ne |
| | | | 164 |
| | 4.2.5 | Visceral Nociceptive Model Induced by Acetic Acid Stimulation in Mice. | 164 |
| | 4.2.6 | Central Nociceptive Model Induced by Radiant Heat Stimulation in Mice | 165 |
| | 4.2.7 | Western Blot Analysis for Determination of COX-1 and COX-2 Protein | |
| | | Expressions | 166 |
| | 4.2.8 | Bio-plex Assay for Determination of IL-1β, IL-2, IL-4, IL-6, IL-10, GM-CS | SF, |
| | | IFN-γ, TNF-α in Rat Paw Tissues | 167 |
| | 4.2.9 | Statistical Analysis | 168 |
| 4.3 | Resu | lts | 169 |
| | 121 | Inhibitory Effect of Er. 8-2 on Carrageenan-induced Paw Edema of Rats | 160 |

| 4.3.2 In | nhibitory Effect of <i>Fr. 8-2</i> on Histamine-induced Paw Edema of Rats1 | 71 |
|------------|--|----|
| 4.3.3 A | Analgesic Effect of Fr. 8-2 in Nociceptive Models of Mice | 73 |
| 4.3.4 II | nhibition of Fr. 8-2 on COX-2 Protein Expression in Rat Paw Tissues1 | 76 |
| 4.3.5 E | Effects of Fr. 8-2 on Levels of IL-1β, IL-2, IL-4, IL-6, IL-10, GM-CSF, | |
| II | FN-γ and TNF-α in Paw Tissues of Rats1 | 78 |
| 4.4 Discus | sions1 | 83 |
| 4.5 Conclu | isions1 | 88 |
| CHAPTER | 5 SUMMARIES AND PROSPECTS OF THE RESEARCH1 | 90 |
| 5.1 Summa | ary and Conclusion of the Research1 | 91 |
| 5.1.1 Id | dentification of the Bioactive Fraction with Anti-thrombotic Activity and | |
| tł | ne Relevant Chemical Constituents | 92 |
| 5.1.2 Id | dentification of the Anti-inflammatory Fraction and the Relevant Chemica | 1 |
| C | Constituents1 | 94 |
| 5.1.3 In | n vivo Anti-inflammatory and Analgesic Activities of Fr. 8-2 and the | |
| N | Mechanism1 | 96 |
| 5.1.4 C | Conclusions 1 | 98 |
| 5.2 Prospe | cts of the Future Studies1 | 99 |
| 5.2.1 B | Bioassay of Pharmacological Activities of the Single Compounds Isolated | |
| fr | rom the Bioactive Fractions of MDQ1 | 99 |
| 5.2.2 F | Turther Investigation on the Chemical Constituents of the Bioactive | |
| F | ractions1 | 99 |
| 5.2.3 It | nteraction of the Chemical Constituents Existed in the Active Fractions2 | 00 |
| 5.2.4 C | Combinative Pharmacological Effects of Two Active Fractions | 00 |
| 5.2.5 S | tudies on Fr. 8-2 as a Potential Botanical Drug | 01 |
| REFERENC | EES | 02 |
| PUBLICATI | IONS2 | 17 |
| PRESENTA | TIONS AND ABSTRACTS2 | 18 |

| PATENTS | 219 |
|------------------|-----|
| | |
| CURRICULUM VITAE | 220 |